StockData
Neuronetics, Inc. logo

Neuronetics, Inc. (STIM) company profile

STIMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30
$1.28+0.03 (+2.40%)

Close on Nov 17, 2026Market cap $97.53MP/E –Yield –

About Neuronetics

Surgical & Medical Instruments & Apparatus, SIC 3841

Neuronetics, Inc. is a medical technology company specializing in neurohealth solutions and transcranial magnetic stimulation (TMS) therapy. Its flagship product is the NeuroStar Advanced Therapy System, an FDA-cleared, non-invasive office-based platform designed to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression. The company sells these therapy systems, recurring treatment sessions, warranties, and practice management tools to healthcare providers, primarily targeting psychiatrists along with primary care physicians and pain management specialists. Additionally, through its subsidiary Greenbrook, it operates mental health centers that deliver TMS procedures and SPRAVATO nasal spray treatments.

The company distributes its products in the United States and selected international markets, including Japan and the European Union. Its operations include a network of 93 treatment centers across 15 U.S. states and support from 658 employees as of year-end 2025. Neuronetics manages product supply and operations from Malvern, Pennsylvania.

Summary of the business section of Neuronetics's latest annual report, written by StockData.

Company profile

Company

Legal name
Neuronetics, Inc.
Founded
2003
Headquarters
Malvern, PA
Address
3222 Phoenixville Pike 19355
Phone
(877) 600-7555
Employees
658, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
STIM
Exchange
Nasdaq
IPO date
Jun 29, 2018
Shares outstanding
76M, Aug 5, 2026
Public float
$129.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1227636
CUSIP
64131A105
ISIN
US64131A1051
FIGI
BBG000QX36J1
Share class FIGI
BBG001SSSWY7
LEI
549300T0911ILTTG7P06
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Nir NaorEVP, CFO & Treasurer500,000
Cory AndersonEVP & Gen. Manager, Greenbrook55,003
Steven PfanstielFormer EVP, CFO and Treasurer836,643
Francis X. Brown IiiInterim PAO19,968
William Andrew MacanEVP, CLO and CS897,270
Daniel L. ReuversPresident and CEO1,500,000
Stephen FurlongEVP, CFO and Treasurer410,053
Robert CascellaDirector798,017
Sasha CucuzDirector3,056,294
Avinash AminDirector30,000
Megan RosengartenDirector170,890
Sheryl L. ConleyDirector251,716
Glenn P. MuirDirector401,816

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.37M$2.20M$2.22M$20–
FY2024$2.43M$1.83M$1.12M$14–
FY2023$2.99M-$1.94M$1.26M$26–
FY2022$2.45M$4.13M$1.27M$62–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Keith J. Sullivan
President and Chief Executive Officer
$728.00K–$3.21M$412.78K$15.54K$4.37M+80%
Steven E. Pfanstiel
Executive Vice President, Chief Financial Officer, and Treasurer
$221.82K$27.95K$2.04M$45.27K–$2.33M–
Stephen Furlong
Executive Vice President, Chief Financial Officer , and Treasurer
$281.87K–$936.60K––$1.22M+3%
W. Andrew Macan
Executive Vice President, Chief Legal Officer, and Corporate Secretary
$463.50K$69.53K$1.46M$93.86K$25.66K$2.11M+100%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 658 full-time employees working collaboratively across our sales and customer support team, in research and development, including clinical, regulatory and certain quality functions, operations and in general and administrative.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?